[ACCESSWIRE]
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharmacyte Biotech Inc (OTC: PMCB), NuGene International Inc (OTC: NUGN), Rainbow Coral Corp (OTC: RBCC) and Elite Pharmaceuticals Inc (OTC: ELTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
To access our full PDF reports for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
PMCB Research Report: http://www.traders-choice.com/pdf?s=PMCB
NUGN Research Report: http://www.traders-choice.com/pdf?s=NUGN
RBCC Research Report: http://www.traders-choice.com/pdf?s=RBCC
ELTP Research Report: http://www.traders-choice.com/pdf?s=ELTP
============
Highlights from today's reports include:
On Friday, October 30, 2015, the U.S. markets finished marginally lower as the NASDAQ Composite ended at 5,053.75, down 0.40%, the Dow Jones Industrial Average edged 0.52% lower, to finish the day at 17,663.54, and the S&P 500 closed at 2,079.36, down 0.48%.
- In line with the broad market, Pharmacyte Biotech Inc's stock declined 3.59% to close the last session at USD 0.1084. The share price vacillated between USD 0.1060 and USD 0.1138. The stock of the clinical-stage biotechnology company recorded a trading volume of 0.88 million shares, which was below its 50-day daily average volume of 1.85 million shares and below its 52-week average volume of 2.37 million shares. Over the last three days, Pharmacyte Biotech Inc's shares have advanced 5.42% and in the past one week it has moved up 2.24%. However, in the last six months, the stock has lost 28.94% and year to date, the shares have shed 39.79%. Additionally, the stock is trading below its 200-day moving average of USD 0.12 and has a price to book ratio of 11.6. The company has a market capitalization of USD 80.57 million. Pharmacyte Biotech, Inc focuses on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
- NuGene International Inc's stock edged higher by 2.42% to close Friday's session at USD 1.27. The company's shares oscillated between USD 1.10 and USD 1.28. The stock recorded a trading volume of 0.09 million shares, which below its 52-week average volume of 0.26 million shares and below its 30-day average volume of 0.92 million shares. The stock has a 52-week range of USD 0.90 – USD 4.54. Over the last three days, NuGene International Inc's shares have declined by 3.79% and in the past one week it has moved down 4.51%. Furthermore, over the last three months, the stock has lost 59.16% and in the past six months, the shares have shed 49.20%. The shares have a 50-day moving average of USD 1.71 while the 200-day moving average is USD 2.25. The company has a market capitalization of USD 50.27 million. NuGene International, Inc. is engaged in developing cosmeceuticals which are combinations of cosmetics and pharmaceuticals, offering medicinal or drug-like benefits.
- The stock of Rainbow Coral Corp gained 3.45% to close the last trading session at USD 0.45. The shares of the company moved in the range of USD 0.40 and USD 0.45. The 52-week range for the stock is USD 0.38 – USD 7.65. A trading volume of 2,535 shares was recorded, which was lower than its 30-day daily average volume of 0.11 million shares. Over the last five days, shares have gained 4.65%. Further, the company is trading at a price to sales ratio of 3.4. In addition, shares are trading below their 50-day moving average of USD 0.80 as well as 200-day moving average of USD 1.25. The company has a market capitalization of 3.81 million. Rainbow Coral Corp, which operates a retail fish store and coral farm facility, announced on November 2, 2015 that it is working on a strategy to increase use of the anti-addiction drug Naltrexone and to expand access to treatment in Canada’s First Nations, Inuit and Métis indigenous populations, where addiction is becoming a serious health problem.
- Elite Pharmaceuticals Inc's stock increased by 0.18% to close Friday's session at USD 0.28. The company's shares fluctuated in the range of USD 0.28 and USD 0.29. A total of 0.74 million shares exchanged hands, which was below its 50-day daily average volume of 0.98 million shares and was also lower than its 52-week average volume of 1.21 million shares. Over the last three days, Elite Pharmaceuticals Inc's shares have advanced 0.35% and in the past one week it has moved up 15.94%. Furthermore, over the last three months, the stock has gained 19.92% and in the past six months, the shares have picked up 25.78%. Further, the company is trading at a price to earnings (P/E) ratio of 7.14 as compared to a historical P/E ratio of 6.42. The stock is trading above its 50-day moving average of USD 0.23. Elite Pharmaceuticals, which has a market capitalization of USD 187.04 million, is a specialty pharmaceutical company engaged in the development and manufacture of oral, controlled-release products.
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice
